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Purpose: To investigate whether transfection with Krüppel-like factor 6 splice variant 1 (KLF6SV1) siRNA can inhibit
proliferation of human lens epithelial cell (HLEC).
Methods: Plasmid containing KLF6SV1 siRNA was used to decrease the level of KLF6SV1 protein in HLEC. The
expression of protein27 kinase inhibition protein 1 (p27kip1) and proliferation cell nuclear antigen (PCNA) was tested with
western blot. Cell proliferation was assayed by 3-(4,5-dimethylthiazolyl-2-)-2,5-diphenyltetrazoliumbromide (MTT)
assay and bromodeoxyuridine (BrdU) incorporation.
Results: KLF6SV1 siRNA can decrease KLF6SV1 expression which leads to increased levels of p27kip1 and decreased
expression of PCNA in HLEC. Cells transfected with pKLF6SV1 siRNA showed less viability compared with the control
group in vitro.
Conclusions: KLF6SV1 siRNA can effectively inhibit HLEC proliferation. It can be regarded as a novel target to treat
posterior capsular opacity (PCO).
Posterior  capsule  opacification  (PCO)  is  the  most
common cause of visual loss after successful cataract surgery
[1,2]. Nd-YAG laser posterior capsulotomy is required for
restoring vision [3]. PCO arises from residual LECs at the
equator  and  under  the  anterior  lens  capsule  after  cataract
surgery. These cells proliferate and migrate onto the posterior
capsule underlying the intraocular lens and into the light path.
Many  of  these  cells  undergo  epithelial  to  mesenchymal
transition,  resulting  in  the  formation  of  fibroblasts  and
myofibroblasts, which lead to capsular opacification [4].
Kruppel-like  factor  6  (KLF6)  single  nucleotide
polymorphisms associated with increased prostate cancer risk
increases  alternative  splicing  of  the  gene  into  three
biologically active, cytoplasmic isoforms, Kruppel-like factor
6 splice variant 1 (KLF6SV1), Kruppel-like factor 6 splice
variant 2 (KLF6SV2), and Kruppel-like factor 6 splice variant
(KLF6SV3),  in  both  normal  and  cancerous  tissues  [5,6].
KLF6SV1 plays an important role in the regulation of cellular
differentiation,  proliferation,  growth-related  signal
transduction, and apoptosis [7,8]. KLF6SV1 is upregulated in
prostate cancer tumors compared with normal prostate tissue
[9,10] and the activity of one of the splice isoforms KLF6SV1
directly opposes KLF6 effects on cell proliferation, colony
formation, invasion, and in vivo tumor growth [11,12]. Our
previous  results  confirmed  that  transfection  with  both
overexpression  of  KLF6  and  S  phase  kinase-interacting
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protein 2 (Skp2) siRNA can inhibit the proliferation of rat lens
epithelial cells (rLEC) [13,14].
There isn’t a previous report on the effect of KLF6SV1
on proliferation of LECs. In the present study, we examined
whether transfection with KLF6SV1 siRNA could upregulate
protein27 kinase inhibition protein 1 (p27kip1) in human lens
epithelial cell (HLEC) (SRA01/04) and their effect on HLEC
proliferation in vitro with 3-(4,5-dimethylthiazolyl-2-)-2,5-
diphenyltetrazoliumbromide (MTT) and bromodeoxyuridine
(BrdU).
METHODS
Reagents: KLF6sv1 was purchased from Invitrogen company
(Grand Island, NY). P27 kip1 antibody and proliferation cell
nuclear  antigen  (PCNA)  was  purchased  from  Santa  cruz
biotechnology  Inc.  (Santa  Cruz,  CA).  Eagle’s  minimal
essential medium (MEM), streptomycin and penicillin were
purchased from Gibco (Grand Island, NY). Fetal calf serum
were  purchased  from  Invitrogen.  Hanks  solution  was
purchased  from  Gibco.  Poly-lysine  was  purchased  from
Sigma (St. louis, MO). Culture plates were purchased from
BD Biosciences (San Jose, CA). Hybond-P polyvinylidene
difluoride (PVDF) membrane was purchased from Amersham
Pharmacia  Biotech  (Piscataway,  NJ).
Methylthiazolyltetrazolium  (MTT)  was  purchased  from
Sigma. The MTT cell proliferation kit was purchased from the
ATCC (Manassas, VA).
Cell culture of HLEC: HLEC (SRA 01/04) were purchased
from the ATCC and cultured in Eagle’s minimal essential
medium (MEM) supplemented with 20% fetal bovine serum
and  gentamicin,  100  U/ml  penicillin,  and  100  μg/ml
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601streptomycin in a six-well plate at 37 °C and 5% CO2 and 95%
air.  All  experiments  were  performed  with  HLEC  cells
between passages 18 and 25 [15].
KLF6SV1 siRNA plasmid construct: Vector pSuppressorNeo
is a vector used to generate biologically active siRNAs from
the U6promoter. Synthetic oligonucleotide primers (5′-GAT
CCC CTG GCG ATG CCT CCC CCG ACt tca aga gaG TCG
GGG GAG GCA TCG CCA TTT TTG GAA A-3′ and 5′-
AGC TTT TCC AAA AAT GGC GAT GCC TCC CCC GAC
tct ctt gaa GTC GGG GGA GGC ATC GCC AGG G-3′) were
annealed  and  then  were  introduced  into  pSuppressor
Neovector.
HLEC  transfected  with  plasmid  containing  KLF6SV1
siRNA, empty vector only, and medium only served as the
experimental groups, the vehicle control group, and the blank
control group, respectively. Transfection was performed in
60  mm  plates  using  3  µg  (1  µg/µl)  vector  in  10µl  of
Metafectene Pro reagent (Biontex, Martinstried, Germany).
After 48 h of transfection, cells were treated with G418 (Life
Technologies, Grand Island, NY) for 2 weeks for positive
clone  selection.  After  G418  treatment,  several  stable
transfectant cells were cloned. Each clone was screened for
expression of KLF6 by western blot analysis [16].
Western blot analysis: HLEC in lysis buffer containing 150
mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1% deoxycholate,
0.1% SDS, 20 mM Tris-HCl, pH 7.5, and protease inhibitors
was crushed by ultrasonic shaft. Protein concentration was
measured  using  absorbance  spectroscopy.  Protein  was
separated on a 10% SDS-polyacrylamide gel and transferred
to nitrocellulose membranes. After blocking with 5% nonfat
milk, the membranes were incubated with primary antibodies
against KLF6SV1, p27  kip1, and PCNA overnight at 4 °C,
followed by incubation with secondary antibodies.
The  membrane  was  then  assayed  using  the  enhanced
chemiluminescent kit (ECL, Thermo Scientific, Rockford, IL)
and scanned with ChemiDoc™Doc XRS+ system (Bio-Rad,
Hercules, CA). The density of each band was obtained using
Quantity One 4.6.2 basic software (Bio-Rad). Values were
expressed as fold change relative to control and normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a
loading control [16].
3-(4,5-dimethylthiazolyl-2-)-2,5-
diphenyltetrazoliumbromide  (MTT)  assay:  Quadruple
samples of rLEC were grown on 96 well plates and were
infected with 2 µg (1 µg/µl) of either of the two vectors in
10 µl of Metafectene Pro reagent, or were not infected. After
2, 4, 6, 8, and 14 days, wells were incubated in a medium
containing yellow tetrazolium for 20 h [16]. Cell viability
ratio=(1-A  value  of  transfection  group/A  value  of  non-
transfection group)×100%.
Cell  proliferation  and  bromodeoxyuridine  (BrdU)
incorporation: Cells (5.0×103) were plated onto a 24-well
multiwell plate (Falcon, Becton Dickinson, Franklin Lakes,
NJ) and allowed to attach for 24 h. The culture medium was
then replaced with fresh medium. Cells were trypsinized and
counted using a cell counter (Coulter Z1; Coulter, FL). For
BrdU  incorporation,  cells  growing  on  coverslips  were
incubated with 10 µmol/l BrdU for 3 h. After fixing in cold
methanol/acetone (1:1) for 10 min, the cells were sequentially
incubated in 1.5 mol/l HCl for 10 min. Then the cells were
washed with PBS and incubated with the mouse anti-BrdU
primary antibody (Santa Cruz, CA) for 1 h. The cells were
washed  four  times  with  PBS.  Cells  with  different  BrdU-
incorporation  patterns  were  analyzed  and  counted  with  a
conventional microscope [17,18].
Statistical analysis: The data were analyzed by the two-tailed
Student t-test using SPSS 10.0 (IBM Inc., Beijing, China) and
a p<0.05 was considered significance.
RESULTS
Downregulation  of  KLF6SV1  in  HLEC  transfected  with
pKLF6SV1 siRNA: We explored the biologic role of KLF6-
SV1  using  siRNA-mediated  gene  silencing  to  specifically
downregulate its expression. There is expression of KLF6SV1
protein in the HLEC transfected with vehicle (Figure 1, lane
3) or without transfection (Figure 1, lane 2). Little expression
of  KLF6SV1  was  detected  in  HLEC  transfected  with
pKLFSV1 siRNA (Figure 1, lane 3).
Upregulation  of  p27kip1  in  HLEC  transfected  with  pKLF6
cDNA: Upregualtion of p27kip1 by transfection of skp2 siRNA
can inhibit the proliferation of rabbit tennon’s fibroblast cells
after  glaucoma  surgery  which  indicate  it  is  important  for
inhibition  of  cell  proliferation  [18].  Expression  of  p27kip1
increased in HLEC transfected with pKLFSV1 siRNA (Figure
2, lane 3) compared with vehicle control (Figure 2, lane 1) and
Figure 1. Downregulation of KLF6SV1 in HLEC transfected with
pKLF6SV1 siRNA. There is KLF6SV1 expression in the HLEC
transfected with vehicle control (lane 1) or blank control (lane 2).
Little expression of KLF6SV1 was detected in HLEC transfected
with  pKLFSV1  siRNA  which  indicates  KLF6SV1siRNA  can
effectively decrease the expression of KLF6SV1 (lane 3).
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it possible for us to investigate the effect of p27 kip1 inhibition
on the proliferation of HLEC.
Downregulation  of  PCNA  in  HLEC  transfected  with
pKLF6SV1  siRNA:  PCNA  is  important  marker  for  cell
proliferation.  Expression  of  PCNA  decreased  in  HLEC
transfected  with  pKLF6SV1  siRNA  (Figure  3,  lane  3)
compared with vehicle control (Figure 3, lane 1) and blank
control (Figure 3, lane 2) which indicated that pKLF6SV1
siRNA can decrease the expression of PCNA.
KLF6SV1 siRNA decrease cell viability of HLEC:
Cell proliferation assay by BrdU—Brdu positive cells
decreased in pKLFSV1 siRNA transfectant cells compared
with vehicle control and blank control (p<0.01 versus vehicle
and blank control, Figure 4).
Cell  viability  assay  by  MTT—Cell  viability  in
pKLF6SV1 siRNA transfected HLEC significantly decreased
Figure  2.  Upregulation  of  p27kip1  in  HLEC  transfected  with
pKLF6SV1  siRNA.  Expression  of  p27kip1  increased  in  HLEC
transfected with pKLFSV1 siRNA (lane 3) compared with vehicle
control (lane 1) and blank control (lane 2).
Figure  3.  Downregulation  of  PCNA  in  HLEC  transfected  with
pKLF6SV1  siRNA.  Expression  of  PCNA  decreased  in  HLEC
transfected with pKLF6SV1 siRNA (lane 2) compared with blank
control (lane 3) and vehicle control (lane 1).
by the 5th day after transfection when compared with vehicle
and blank control (Figure 5).
DISCUSSION
PCO  is  the  most  common  postoperative  complication  of
cataract surgery that causes visual loss [19]. Residual LECs
at the equator and under the anterior lens capsule after surgery
can proliferate and result in the formation of posterior capsular
opacification [20].
KLF6-SV1  can  decrease  the  level  of  cellular
differentiation,  development,  proliferation,  growth-related
signal transduction, and apoptosis [21-24]. KLF6 inactivation
and KLF6-SV1 overexpression have been associated not only
with  the  progression  of  several  human  cancers  but  more
importantly with patient survival [25-29].
Although  KLF6-SV1  expression  is  present  in  both
normal and cancerous tissues, the expression of this isoform
is  significantly  upregulated  in  multiple  cancers,  including
prostate cancer, glioblastoma, and lung cancer [30,31].
Figure  4.  Cell  proliferation  assay  by  BrdU.  Brdu  positive  cells
decreased  in  pKLFSV1  siRNA  transfected  cells  compared  with
HLEC of vehicle control and blank control (p<0.01 versus vehicle
and blank control).
Figure  5.  Cell  viability  assay  by  MTT.  Cell  viability  in  HLEC
significantly  decreased  by  the  5th  day  after  transfection  with
pKLF6SV1 siRNA compared with vehicle control and blank control.
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have a prognostic association with lung and prostate cancers.
In prostate cancer, increased expression levels of KLF6-SV1
at the time of prostatectomy were associated with a >4-year
survival difference in men. Patients with high levels of KLF6-
SV1 expression had a median survival of approximately 30
months versus 80 months in patients with low KLF6-SV1
expression [32]. Small interfering RNA (siRNA) has been
demonstrated to be highly specific to down-regulate KLF6-
SV1 expression [31,32].
Skp2 siRNA and overexpression of KLF6 can inhibit
proliferation of LEC. Upregulation of p27kip1expression can
inhibit  the  proliferation  of  rabbit  LEC  which  indicates
p27kip1 is important for regulation of cell proliferation [16,
17].  Our  present  study  showed  that  transfection  with
pKLF6SV1 siRNA can inhibit proliferation of HLEC in vitro.
In summary, this study has delineated the role of KLF6SV1 in
inhibition  the  proliferation  of  HLEC  in  vitro.  Increased
expression of p27kip1 and decreased expression of PCNA after
transfection with KLF6SV1 siRNA suggest their important
role for inhibition of cell proliferation.
Narla  et  al.  [31]  found  that  KLF6SV1  siRNA  can
effectively  enhance  the  apoptosis  of  cancer  cells  which
indicate it can be used for treatment of cancer in the future.
Furthermore,  Our  results  also  showed  that  We  show  that
KLF6SV1  siRNA  inhibit  the  proliferation  of  HLEC  by
increasing the expression of p27kip1 and decreasing PCNA
expression in HLEC. This response is consistent with KLF6
overexpression in rat lens epithelial cells.
In conclusion, the present work demonstrates for the first
time that transfection with KLF6SV1 siRNA can effectively
inhibit proliferation of HLEC in vitro which indicates it can
be novel target for treatment of PCO. Although KLF6SV1 is
a powerful way to inhibit the proliferation of HLEC, further
work  is  needed  before  this  approach  can  be  used  for  the
treatment of human disease.
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